A Phase 3 interventional study of Esomeprazole (D961H) twice daily and Esomeprazole (D961H) once daily in Refractory Reflux Esophagitis, sponsored by AstraZeneca. Completed at 63 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-08-27.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Esophagitis, Peptic by AstraZeneca — none open to participants now, none under way, none of them phase 3. Esophagitis, Peptic · AstraZeneca.
Among the 12 studies in Esophagitis, Peptic by AstraZeneca, this one is one of 2 that started in 2012, is one of 5 in phase 3, and was the 8th registered.
83 studies on the registry are indexed under Esophagitis, Peptic; 16 are open to participants now.
Browse Esophagitis, Peptic studies →None of the 12 studies in Esophagitis, Peptic by AstraZeneca is open now. The open studies under Esophagitis, Peptic, anywhere →
Of the 8 Esophagitis, Peptic studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,398 is above the median of 135 across 60 interventional studies indexed under Esophagitis, Peptic.
Median enrollment 114 across the 8 interventional studies, 2,643 across the 4 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Esophagitis, Peptic by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of esomeprazole magnesium salt) with refractory reflux esophagitis after 8 weeks of standard Proton-pump inhibitor (PPI) therapy by assessment of presence/absence of inflammation (esophagitis) at Week 8 according to the Los Angeles (LA) classification
A multicentre, randomised, double-blind, parallel-group, comparative study to compare the efficacy and safety of D961H 20 mg twice daily oral administration and D961H 20 mg once daily oral administration in patients with refractory reflux esophagitis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double-blinded
Drug: Esomeprazole (D961H) twice daily
Double-blinded
Drug: Esomeprazole (D961H) once daily
One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and in the evening
One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and one corresponding placebo capsule in the evening
Percentage of Participants With Healing of RE Who Were Graded "O" at Week 8 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles Classification
Percentage of participants with healing of reflux esophagitis (RE) who were graded "O" (No RE) at Week 8 out of participants who were graded "A" (least severe) to "D" (most severe) at baseline according to Los Angeles classification
Time frame: 8 Weeks
Percentage of Participants With Healing of RE Who Were Graded "O" at Week 4 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles Classification
Percentage of participants with healing of reflux esophagitis (RE) who were graded "O" (No RE) at Week 4 out of participants who were graded "A" (least severe) to "D" (most severe) at baseline according to Los Angeles classification
Time frame: 4 Weeks
Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Heartburn at Week 4
Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -heartburn at Week 4 (on Day 29) based on the Kaplan-Meier method.
Time frame: 4 Weeks
Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Acid Regurgitation at Week 4
Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -acid regurgitation at Week 4 (on Day 29) based on the Kaplan-Meier method.
Time frame: 4 Weeks
Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Abdominal Pain at Week 4
Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -abdominal pain at Week 4 (on Day 29) based on the Kaplan-Meier method.
Time frame: 4 Weeks
Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Difficulty of Swallowing at Week 4
Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -difficulty of swallowing at Week 4 (on Day 29) based on the Kaplan-Meier method.
Time frame: 4 Weeks
Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Sleep Disturbance at Week 4
Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -sleep disturbance at Week 4 (on Day 29) based on the Kaplan-Meier method.
Time frame: 4 Weeks
First subject enrolled on 25 August 2012. Last subject completed on 30 May 2014.
| Milestone | D961H 20 mg BID | D961H 20 mg QD + Placebo |
|---|---|---|
| Started | 145 | 142 |
| Completed | 142 | 131 |
| Not completed | 3 | 11 |
| Withdrew: Investigator decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Adverse event | 2 | 6 |
| Withdrew: Eligibility criteria not fulfilled | 0 | 2 |
Percentage of participants with healing of reflux esophagitis (RE) who were graded "O" (No RE) at Week 8 out of participants who were graded "A" (least severe) to "D" (most severe) at baseline according to Los Angeles classification
| Percentage of participants | D961H 20mg Bid | D961H 20mg QD + Placebo |
|---|---|---|
| Percentage of Participants With Healing of RE Who Were Graded "O" at Week 8 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles Classification | 92.4 (86.9 to 95.7) | 68.6 (60.5 to 75.7) |
Percentage of participants with healing of reflux esophagitis (RE) who were graded "O" (No RE) at Week 4 out of participants who were graded "A" (least severe) to "D" (most severe) at baseline according to Los Angeles classification
| Percentage of participants | D961H 20mg Bid | D961H 20mg QD + Placebo |
|---|---|---|
| Percentage of Participants With Healing of RE Who Were Graded "O" at Week 4 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles Classification | 81.4 (74.3 to 86.9) | 48.6 (40.4 to 56.8) |
Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -heartburn at Week 4 (on Day 29) based on the Kaplan-Meier method.
| Percentage of participants | D961H 20mg Bid | D961H 20mg QD + Placebo |
|---|---|---|
| Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Heartburn at Week 4 | 81.1 (74.3 to 86.9) | 72.8 (40.4 to 56.8) |
Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -acid regurgitation at Week 4 (on Day 29) based on the Kaplan-Meier method.
| Percentage of participants | D961H 20mg Bid | D961H 20mg QD + Placebo |
|---|---|---|
| Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Acid Regurgitation at Week 4 | 73.1 (74.3 to 86.9) | 61.2 (40.4 to 56.8) |
Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -abdominal pain at Week 4 (on Day 29) based on the Kaplan-Meier method.
| Percentage of participants | D961H 20mg Bid | D961H 20mg QD + Placebo |
|---|---|---|
| Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Abdominal Pain at Week 4 | 68.1 (74.3 to 86.9) | 59.1 (40.4 to 56.8) |
Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -difficulty of swallowing at Week 4 (on Day 29) based on the Kaplan-Meier method.
| Percentage of participants | D961H 20mg Bid | D961H 20mg QD + Placebo |
|---|---|---|
| Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Difficulty of Swallowing at Week 4 | 78.6 (74.3 to 86.9) | 74.1 (40.4 to 56.8) |
Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -sleep disturbance at Week 4 (on Day 29) based on the Kaplan-Meier method.
| Percentage of participants | D961H 20mg Bid | D961H 20mg QD + Placebo |
|---|---|---|
| Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Sleep Disturbance at Week 4 | 91.2 (74.3 to 86.9) | 89.3 (40.4 to 56.8) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| D961H 20 mg BID | — | 1/145 (0.7%) | 8/145 (5.5%) |
| D961H 20 mg QD + Placebo | — | 3/142 (2.1%) | 9/142 (6.3%) |
| Event | D961H 20 mg BID | D961H 20 mg QD + Placebo |
|---|---|---|
| GastritisGastrointestinal disorders | 0/145 | 1/142 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/145 | 1/142 |
| Parotid abscessInfections and infestations | 0/145 | 1/142 |
| Pancreatic pseudocystGastrointestinal disorders | 1/145 | 0/142 |
| Event | D961H 20 mg BID | D961H 20 mg QD + Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 8/145 | 9/142 |
It was found that 2 patients in D961H 20 mg QD + Placebo group had no refractory RE after randomisation. Therefore, these two patients were excluded from the full analysis set, which was the primary analysis set of this study and was used for summaries of baseline characteristics and outcome measures.
| Age, Continuous(Years) | D961H 20 mg BID | D961H 20 mg QD + Placebo | Total |
|---|---|---|---|
| Mean | 64.7 ± 13.87 | 61.7 ± 14.72 | 63.2 ± 14.35 |
| Age, Customized(Participants) | D961H 20 mg BID | D961H 20 mg QD + Placebo | Total |
|---|---|---|---|
| <65 | 68 | 69 | 137 |
| >=65 | 77 | 71 | 148 |
| Sex: Female, Male(Participants) | D961H 20 mg BID | D961H 20 mg QD + Placebo | Total |
|---|---|---|---|
| Female | 69 | 70 | 139 |
| Male | 76 | 70 | 146 |
| Race/Ethnicity, Customized(Participants) | D961H 20 mg BID | D961H 20 mg QD + Placebo | Total |
|---|---|---|---|
| Asian | 145 | 140 | 285 |
The record gives a start of Aug 2012, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.